STEPHEN(ANSELL((ROCHESTER)(
(
CHECKPOINT*INHIBITORS*AND*BISPECIFIC*ANTIBODIES!
! Stephen(M.(Ansell,(MD,(PhD,(Mayo(Clinic(
!
Patients! with! B>cell! non>Hodgkin! lymphoma! who! fail! standard! therapy! have! a! very! poor!
prognosis.!!Novel!therapies!are!therefore!needed!for!these!patients!and!treatments!that!can!
engage!the!immune!system!may!be!able!to!redirect!effector!cells!to!lyse!the!malignant!B>
cells.!!Lack!of!adequate!immune!activation!or!inability!to!identify!and!target!the!malignant!
cell!are!common!reasons!for!lack!of!an!effective!antitumor!immune!response!in!lymphoma.!!
Antibodies! targeting! immune! checkpoints! (to! activate! the! effector! cells)! and! bispecific!
antibodies!(that!promote!targeting!of!the!malignant!cell)!are!therefore!potential!treatments!
that! can! overcome! these! immunological! hurdles.! ! While! immune! checkpoint! blockade!
targeting! T>cells! is! only! effective! in! a! subset! of! lymphoma! patients,! innate! immune!
checkpoint! approaches! targeting! macrophages! may! be! more! successful.! ! In! contrast! to!
immune!checkpoint!blockade,!bispecific!antibodies!targeting!both!the!malignant!B>cells!and!
intratumoral!T>cells!demonstrate!responses!in!a!far!greater!proportion!of!patients!with!non>
Hodgkin! lymphoma! and! are! even! effective! in! patients! who! have! failed! cellular! therapies.!!
These!immunological!approaches!provide! evidence!that!redirecting! cells!from!the!immune!
system! to! target! the! tumor! results! in! clinical! benefit! and! improved! outcomes! for! patients!
with!non>Hodgkin!lymphoma.!
!!
Suggested!Reading!
• Kline!J,!Godfrey!J,!Ansell!SM.!The!immune!landscape!and!response!to!immune!checkpoint!
blockade!therapy!in!lymphoma.!Blood.!2020!Feb!20;135(8):523>533.!
• Ansell!SM.!The!Highs!and!Lows!of!Immune>Checkpoint!Blockade!in!Lymphoma.!Cancer!Immunol!
Res.!2019!May;7(5):696>700.!
• Armand!P,!Rodig!S,!Melnichenko!V,!et!al.!Pembrolizumab!in!Relapsed!or!Refractory!Primary!
Mediastinal!Large!B>Cell!Lymphoma.!J!Clin!Oncol.!2019!Dec!1;37(34):3291>3299.!!
• Advani!R,!Flinn!I,!Popplewell!L,!et!al.!CD47!Blockade!by!Hu5F9>G4!and!Rituximab!in!Non>
Hodgkin's!Lymphoma.!N!Engl!J!Med.!2018!Nov!1;379(18):1711>1721.!!
• Goebeler!ME,!Knop!S,!Viardot!A,!et!al.!Bispecific!T>Cell!Engager!(BiTE)!Antibody!Construct!
Blinatumomab!for!the!Treatment!of!Patients!With!Relapsed/Refractory!Non>Hodgkin!Lymphoma:!
Final!Results!From!a!Phase!I!Study.!J!Clin!Oncol.!2016!Apr!1;34(10):1104>11.!
!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES